Navigation Links
Drug Combinations That May Cause Major Drug Interactions Common Among Seniors Who Take Antidepressants, According to Thomson Reuters Research
Date:12/17/2010

ANN ARBOR, Mich., Dec. 17, 2010 /PRNewswire/ -- More than half of older Americans who were prescribed antidepressants for the first time were already taking a medication that could adversely interact with the antidepressant, according to a new study from Thomson Reuters.

For one-fourth of the seniors in the study, these were potentially major drug interactions.

The research, published by the American Journal for Geriatric Psychiatry, illustrates the complexity and challenges of prescribing antidepressants to older patients.

"We found a concerning degree of potentially harmful drug combinations being prescribed to seniors," said Tami Mark, Ph.D., the paper's lead author and director of analytic strategies at Thomson Reuters.

Among the 39,512 new antidepressant users in the study, 25.4 percent were prescribed antidepressants and another medication that could cause a major interaction. An additional 36.1 percent had potential moderate interactions and 38.5 percent had minor or no interactions.

Pain medications were most often identified as having the potential for major interactions with antidepressants, accounting for more than one quarter of all potential major interactions among seniors in the study.

"These findings reinforce the need for clinicians to be aware of potential drug-drug interactions and the importance of close patients monitoring," Mark said.

The presence of contraindications or interactions increased the probability of patients switching antidepressants by 19.5 percent.  

The study also found that 5.6 percent of study subjects had a documented side effect from the antidepressants they were prescribed, most often insomnia, somnolence and drowsiness. Overall, the presence of a side effect was associated with a 4.7 percentage point increase in drug switching (from 16.5% to 21.7%) and a 3.7 percentage point increase in discontinuation of treatment (from 22% to 25.7%).

Data for the study were derived from the Thomson Reuters MarketScan® database of Medicare claims. Potential drug interactions were identified using Thomson Reuters DRUG-REAX® System. Study subjects, who were aged 65 years or older, were new antidepressant users who were diagnosed with depression between July 1, 2001, and December 31, 2006.  

The study was funded by Sanofi Aventis. Co-authors include Vijay N. Joish, Ph.D., now with Bayer Pharmaceuticals; Joel W. Hay, Ph.D, from the University of Southern California School of Pharmacy; and David V. Sheehan, M.D., M.B.A., from the University of South Florida College of Medicine.

An abstract is available here: http://journals.lww.com/ajgponline/Abstract/publishahead/Antidepressant_Use_in_Geriatric_Populations__The.99747.aspx

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, healthcare and science and media markets, powered by the world's most trusted news organization.  With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs 55,000 people and operates in over 100 countries.  For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
2. Global Partners Join Forces to Speed Development of New TB Drug Combinations
3. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
4. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
5. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
6. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
7. Study Highlights Incidence of Cardiovascular Disease-Related Events and All-Cause Hospitalizations Associated with BYETTA® Compared to Insulin, Thiazolidinediones, Sulfonylureas, Metformin and Januvia®
8. Survey Reveals Majority of Americans Hold onto Myths About What Causes Colds and How to Treat Them
9. HART Health: Headaches Cause More Than $61 Billion a Year in Lost Time
10. American Association for Respiratory Care (AARC) Joins DRIVE4COPD to Raise Awareness of Nations 4th Leading Cause of Death
11. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... PARK , Israel , December 7, ... announced today the signing of a memorandum of understanding with Korean ... synergy between the companies will assist in expediting Kadimastem,s entry into ... in innovative treatment for severe diseases in general and ALS and ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016  Organovo Holdings, ... three-dimensional biology company focused on delivering scientific and ... announced that Chairman and Chief Executive Officer ... VirtualInvestorConferences.com on Wednesday, December 14, 2016 at 1:00 ... who are not yet familiar with the Company, ...
(Date:12/7/2016)... 7, 2016 The global  ... value of USD 3.9 billion by 2024, based ... Inc. The growth of the market is attributed ... technological advancements by the market players. Demand for ... increasing donation, rising awareness about transfusion-transmitted diseases, and ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... It is vital for any lab to secure ... data. The team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools ... need to operate in a GLP (Good Laboratory Practice) fashion. , With features designed ...
(Date:12/7/2016)... Boston, MA (PRWEB) , ... December 07, 2016 , ... ... They are sisters and wives, brothers and fathers, from New England and around ... illness and its stigma, and are brought together in a beautiful and compelling new ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers Insurance Agency, ... in the Sacramento/Folsom region, is initiating a charity event to raise support and ... Another Chance treatment center in Sacramento works to provide area teens and families ...
(Date:12/7/2016)... ... ... A. Kevin Spann Insurance, a New York-based firm offering insurance and financial ... charity drive to raise funds that will benefit the Marine Corps League. , The ... FMF Corpsmen. Working closely with the MCL, the A. Kevin Spann team plans to ...
(Date:12/7/2016)... ... 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel of ... of proceeds to two local organizations: North Chicago Animal Control and Friends and Our ... a team of authorized and trained volunteers who support rescued animals held in the ...
Breaking Medicine News(10 mins):